Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 5, 2023 /PRNewswire/ -- Sirnaomics Ltd. , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi...

Related Keywords

United States ,China ,Francois Lebel ,Sirnaomic Galahead ,Patrick Lu ,Group Or Sirnaomics ,Group Factor Xi Program ,Prnewswire Sirnaomics Ltd ,Stock Code ,Executive Director ,Chief Executive Officer ,Chief Medical Officer ,Markets ,